Journey Medical Corp (DERM)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Financial Position (from SEC Filings)

$27.2M
Cash & Equivalents
$2.9M
Quarterly Burn Rate
$190M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (4 Assets)

DrugPhaseIndications
GLYCOPYRRONIUM TOSYLATE
QBREXZA 		APPROVED —
CROTAMITON
EURAX 		APPROVED —
SULCONAZOLE NITRATE
EXELDERM 		APPROVED —
MINOCYCLINE HYDROCHLORIDE
AMZEEQ 		NDA Complication,Postoperative, Confluent and Reticulated Papillomatosis (CARP), Hyperhidrosis, Palmar Hyperhidrosis, Papulopustular Rosacea, Pharmacokinetics, Rosacea, Stoma

Upcoming Catalysts

DateEventDrug
2027-07-01 Phase3 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04333576 Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea R... PHASE3 Active Not Recruiting 800

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for DERM.

SEC EDGAR Filings

All SEC filings for Journey Medical Corp on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.